Clinical trials: Menstrually Related Migraine
- Condition Menstrually Related Migraine
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Migraine
A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM.
- Trial name
- NCT00475514
- Testing
- Frovatriptan 2.5mg QD, Frovatriptan 2.5 mg BID
- Volunteers
- 500 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs).
- Trial name
- MAM (NCT01035983)
- Testing
- Frovatriptan 2.5 mg
- Where
- 5 sites in Germany, Hungary and 3 more
- Volunteers
- 550 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company